Dinner Meeting to be held on May 21 hosted by Piper Sandler.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics announces results from Phase 2a trial of bexotegrast
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics price target lowered to $45 from $54 at RBC Capital
- Pliant Therapeutics price target raised to $48 from $47 at Oppenheimer
- Pliant Therapeutics price target lowered to $36 from $48 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com